TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
|Slideshows|August 7, 2018
Diabetes News Roundup: July 2018
Author(s)Mark L. Fuerst
Highlights include how cost-effective insulin reduces hospital visits; prevalence of restrictive lung disease in T2DM patients; and the wonders of self-monitoring for cost of care.
Advertisement
Advertisement
Related to this article
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
Compared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
3
Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories
4
Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2D
5